Novel Immune Activators

About

Chronic viral infections and cancer can lead to immune exhaustion, where the immune system loses its ability to combat infection. Immunotherapy is an exciting field for future treatments of chronic infections and various cancers, whereby a patient’s immune system is strengthened. A key characteristic of immune exhaustion is the decrease in cytotoxic T-lymphocytes (CTL) populations. CTLs selectively attack diseased cells whilst leaving healthy cells intact, an advantageous trait when fighting disease. We have discovered a new pathway through which immune exhaustion can be overcome. The pathway is a promising target for first-in-class immunotherapies that stimulate the increase of CTL numbers by up to 5 times. Scientists have run proof of concept studies and obtained in vivo validation, using disease models for melanoma and chronic viral infection. This technology is in the early stages of development and Innovations is now looking for co-development or licensing partners with aims towards drug development. Please press “Connect” and we will send you 6 supporting Powerpoint slides on this technology. When contacting us, please quote reference number 5897.